Toshiba changes include Sharma's exit
Several personnel changes took place at Toshiba America MedicalSystems last month, including the departure of vice presidentof corporate marketing Ravi Sharma. Toshiba, of Tustin, CA, declinedto comment on the reasons for Sharma's exit other than to
Several personnel changes took place at Toshiba America MedicalSystems last month, including the departure of vice presidentof corporate marketing Ravi Sharma. Toshiba, of Tustin, CA, declinedto comment on the reasons for Sharma's exit other than to sayhe left to pursue other interests. Sharma joined the company in1989 and held the position for two years.
Other changes at the company were on a brighter note. SuzanneCertain was named director of ultrasound marketing and Dean Winterwas tapped as director of ultrasound national sales. The promotionsdenote their assumption of additional responsibilities after theexit of Philip Smith, who headed the ultrasound business unituntil leaving Toshiba in April (SCAN 4/12/95).
In nuclear medicine, Steve Sickels' title has been changed todirector of the nuclear medicine business unit. The promotionreflects his authority over Toshiba's nuclear medicine softwaredevelopment group, which will be moved from Japan to Toshiba AmericaMRI headquarters in South San Francisco, CA (SCAN 7/6/95).
In addition, Tom Bogle was named vice president of full linesales, overseeing sales for the CT, MRI, nuclear medicine, vascularand general x-ray product lines, as well as Toshiba's full-linestrategic accounts department.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
